cyrilzakka/clinical-trials huggingface dataset:
The Effect of Neurophysiological Facilitation Techniques on Health Parameters in Early Stages After Open Heart Surgery

In this study, researchers aimed to investigate effects of neurophysiological facilitation on functional capacity and respiratory parameters of patients who underwent open heart surgery.

Do neurophysiological facilitation techniques improve individuals' respiratory parameters more than phase 1 cardiac rehabilitation?

Do neurophysiological facilitation techniques improve individuals' functional capacity more than phase 1 cardiac rehabilitation?

Researchers will apply phase 1 cardiac rehabilitation to both groups to see the effectiveness of neurophysiological facilitation techniques.

In this study, researchers aimed to investigate effects of neurophysiological facilitation on functional capacity and respiratory parameters of patients who underwent open heart surgery.

The study was performed on 32 patients who underwent open heart surgery. Patients divided into two groups which study group (n=18) and control group (n=14).

Range of motion, breathing and mobilization exercises within the scope of phase 1 cardiac rehabilitation program were applied to the control group; in addition to the phase 1 cardiac rehabilitation program, neurophysiological facilitation techniques (perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction) were applied to the study group.

Sociodemographic features and disease-specific findings were recorded on the first postoperative day .

Vital signs, functional capacity, pulmonary function, fatigue and dyspnea of every patient were recorded before and after each treatment on the first four postoperative days.

Functional capacity was evaluated using Timed Up and Go (TUG) test and 2-Minutes Walking test (2MWT). Pulmonary function was examined using a peak flow meter and respiratory muscle strength was measured using an intraoral pressure measurement device. In addition, fatigue and dyspnea perception was measured using Modified Borg Scale.

Before the first day treatment and after the last day treatment of the four-day treatment, patients' fatigue severity were assessed with using Fatigue Severity Scale (FSS), anxiety and depression level with using Hospital Anxiety Depression Scale (HADS), fear of movement with using TAMPA Kinesiophobia Scale and life quality with using the Minnesota Heart Failure Questionnaire.

Before each treatment chest circumference measurements were taken, and the perceived pain severity was recorded using Visual Analog Scale (VAS).

Eligibility Criteria:
Inclusion Criteria:

* Having open heart surgery for the first time,
* Being between the ages of 18-75,
* Being fully cooperative

Exclusion Criteria:

* Having facial, sternum and rib fractures,
* Having chronic renal failure,
* Development of cerebrovascular accident,
* Having cognitive dysfunction,
* Development of deep vein thrombosis in the post-operative period,
* Having neuromuscular disease,
* Having an orthopedic disability,
* Intubation time longer than 24 hours,
* Staying in intensive care for more than 48 hours
Adding Shock Wave Therapy to Kinesio Taping Improves Carpal Tunnel Syndrome in Physical Therapist Females.

PURPOSE: To investigate the effect of adding Shock wave therapy to kinesio taping on relieving carpal tunnel syndrome symptoms in physical therapist females.

BACKGROUND: shockwave therapy is a popular non-invasive therapeutic modality in the medical field for the treatment of numerous musculoskeletal disorders. Shockwaves can generate interstitial and extracellular responses, producing many beneficial effects such as: pain relief, vascularization, protein biosynthesis, cell proliferation, neuro and chondroprotection, and destruction of calcium deposits in musculoskeletal structures. shockwave combined with conventional physiotherapy is an effective noninvasive treatment for mild-to-moderate carpal tunnel syndrome that produces greater and longer-lasting results than conventional physiotherapy alone HYPOTHESES: Adding Shock wave therapy to kinesio taping has positive effects on carpal tunnel syndrome in physical therapist females.

RESEARCH QUESTION: Does adding Shock wave therapy to kinesio taping has positive effects on carpal tunnel syndrome in physical therapist females?


Eligibility Criteria:
Inclusion Criteria:

* Patients aged between 20 and 40 years
* diagnosed as having mild and moderate carpal tunnel syndrome through clinical parameters and nerve conduction studies (NCSs),

Exclusion Criteria:

- Having any systemic diseases such as renal failure, peptic ulcer, diabetes mellitus, hypothyroidism, coagulopathy, inflammatory rheumatic disease, having a cardiac pacemaker, cervical radiculopathy, polyneuropathy or brachial plexopathy, systemic corticosteroid use, fracture or trauma history in the forearm and wrist pregnancy and lactation, having received a carpal tunnel syndrome surgery, thoracic outlet syndrome or severe carpal tunnel syndrome.
Neuropsychiatric Research Databases for People With Intellectual Disabilities and Epilepsy (REFINE)

This study consists of two parts:

Part One: De-identified Database

The goal of this part is to establish a research database containing de-identified data about People with Intellectual Disabilities (PwID) and epilepsy, collected from three NHS sites across England and Wales. Researchers will gather information from participants' medical records, including clinical details, epilepsy history, and medications, and will enter this data into a secure database where all identifying details are removed. This part of the study aims to determine whether it's possible to identify eligible participants, collect complete datasets for each participant, and identify any issues that may affect the quantity and quality of data. These findings will help inform a potential future study that could involve 20 or more sites.

Part Two: Research Register

The goal of this part is to create a research register of individuals with PwID and epilepsy. Participants will be approached and asked for their consent to collect their personal and clinical data, which will help identify those willing to take part in future ethically approved research projects. As in Part One, researchers will collect data from medical records. Participants who consent to be included in the register may be contacted by external researchers for future studies. The aim is to facilitate national collaboration by enabling data sharing between research projects, thereby improving the ability to answer more questions and enhance patient care. This part of the study will test whether it's possible to determine screening and recruitment rates at each site, develop and evaluate recruitment processes, and assess how researchers leading other approved studies can obtain permission to use the register. Additionally, it will evaluate whether it's possible to collect a complete dataset for each participant.


Eligibility Criteria:
The de-identified database:

Inclusion Criteria:

* Clinical diagnosis of ID in medical records.
* Clinical diagnosis of epilepsy in medical records.
* Patient is over the age of 18 years old.
* Under the current care of specialist ID or epilepsy services at one of the three participating NHS Trusts.

Exclusion Criteria:

* Other neurodevelopmental disorders without ID.
* Patient is recorded on the National Data Opt-out as not wishing their data to be used for research/audit.

The research register:

Inclusion Criteria:

* Clinical diagnosis of ID in medical records.
* Clinical diagnosis of epilepsy in medical records.
* Under the current care of specialist ID or epilepsy services at one of the three participating NHS Trusts.
* Between the ages of 18 and 30 at the time of consent.
* Participant has the capacity to be able to provide consent for themselves, or a personal consultee is able to provide an opinion on the views and feelings of the potential participant.
* Patients (or personal consultee) must be able to communicate in English (or Welsh in Welsh site).

Exclusion Criteria:

- Other neurodevelopmental disorders without ID.
ES Catheter vs Cryoablation After Pectus Surgery

Participants will be randomized to receive ES catheter or cryoablation for pain management after the Nuss procedure. The goal of this study is to compare the following between the two groups:

* Time to achieve short-term physical therapy goals and long-term functional outcomes
* Compare immediate and long-term postoperative opioid use
* Compare numbness on chest of postoperative day 1 and the return of sensation to baseline
* Compare the incidence of neuropathic pain and other complications

Participants will receive surveys for up to 12 months postoperatively.


Eligibility Criteria:
Inclusion Criteria:

* Age 12 - 21 years
* History of pectus excavatum
* Scheduled for Nuss procedure

Exclusion Criteria:

* Prior pectus repair
* Other concomitant surgeries
* Chronic pain conditions including Ehlers Danlos Syndrome
* Non-English speaking - rationale: the questionnaires used in the study are in English language and the social and cultural factors of pain perception of non-English speaking patients could affect the study power
* Severe developmental delays including cognitive (difficulties understanding), motor (cerebral palsy or muscular dystrophy), and speech delays (difficulties communicating)
* History of or active renal or liver disease
* Major surgery requiring opioids in the last 2 years
* Severe respiratory problems (such as obstructive sleep apnea, cystic fibrosis, pulmonary fibrosis, or pneumonia within the last month)
* Cardiac conditions including, but not limited to, cyanotic heart disease, hypoplastic left ventricle, arrhythmia, uncontrolled hypertension with ongoing treatment, Kawasaki disease, or cardiomyopathies. Participants with asymptomatic valvular lesions or defects may be included
* BMI \>35
* Pregnant or breastfeeding females
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients with GPC3-positive Advanced Solid Tumors

This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.

AST-201 is a novel aptamer drug conjugate (ApDC) investigational agent with demonstrated preclinical efficacy in GPC3-positive tumor models. This Phase 1 clinical study aims to investigate the safety, tolerability, and preliminary efficacy of AST-201, targeting GPC3-positive advanced solid tumors. The study consists of two parts: Phase 1a and Phase 1b.

In Phase 1a, AST-201 will be administered in a dose escalating manner across cohorts of patients to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). In this dose-escalation phase, patients will receive AST-201 as a single agent, with safety, tolerability, and pharmacokinetic (PK) profiles assessed. In Phase 1b, patients will receive AST-201 at the RP2D across specific GPC3-positive tumor types to further explore safety and efficacy. This expansion phase focuses on assessing anti-tumor efficacy and overall safety in a broader patient population. Data collected from this study will support future clinical development of AST-201 in GPC3-positive advanced solid tumors.

Eligibility Criteria:
Inclusion Criteria

* Male and female aged ≥19 years
* Histologically and/or cytologically diagnosed as the advanced recurrent solid tumor
* GPC3-positive confirmed by IHC test
* At least 1 measurable or non-measurable but evaluable lesion as defined per RECIST v1.1 (modified RECIST for hepatocellular carcinoma)
* ECOG performance status of 0 or 1
* Life expectancy at least 12 weeks
* Adequate hematologic, hepatic, renal, and heart/coagulation function
* Child-Pugh Class of A for HCC

Exclusion Criteria

* Subjects with ischemic heart disease
* Subjects with anti-tumor treatment within 4 weeks
* Subjects with comorbidities such as uncontrolled hypertension, heart failure, etc.
* Pregnant or potentially pregnant and lactating woman
Current Situation of Health Care in Women With HBV or HCV Infection

A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.

Some of the sociocultural factors may prevent women infected with HBV or HCV benefiting from quality health care. Limited articles have ever reported the situation of health care in women with viral hepatitis. A previous study found that low HCV knowledge was observed in females, which was related to a lower willingness to be treated for HCV. Besides that, in other disease areas like hypertension, studies found that females have less awareness of their disease but have higher control over it compared with males. These findings might reflect the differences in health literacy levels which might influence disease outcomes, healthcare-seeking and adherence to treatment. This research aims to fill the data gaps of the gender differences in cascade of care in HBV and HCV, to facilitate patient activation, especially for women.

So far, data on the current health care status in HBV-infected women is scarce. With the expansion of treatment indications recommended by China CHB guidelines, more female patients will have the opportunity to gain timely and necessary treatment. This study will analyze the cascade of care by observing the duration from diagnosis to treatment and treatment adherence for women. And this knowledge will serve as a guide for interventions for the management of viral hepatitis, as well as effectively finding and activating patients who meet treatment criteria but are not being treated.

Eligibility Criteria:
Inclusion Criteria:

HBV Cohort -

* ≥18 years old
* serum HBsAg positive for \>6 months
* Treatment naïve or,
* Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment

HCV Cohort -

* ≥18 years old
* HCV-Ab positive
* HCV RNA positive
* Treatment naïve or,
* Patients who had been previously treated for HCV with a regimen containing interferon and not had a sustained virologic response.

Exclusion Criteria:

* HBV/HCV Co-infection
* HIV
* History of hepatic decompensation or hepatocellular carcinoma
* Other carcinoma
* Other severe liver disease
* Severe Comorbidity like cardiovascular disease, diabetes etc.
* Patients who had discontinued previous HCV treatment because of an adverse event.
* Patients who had previously received any nucleotide analogue HCV NS5B inhibitor or any NS5A inhibitor
* Patients who had discontinued previous HBV treatment because of an adverse event.
Validity and Reliability of the WAL-K Test

Adapting the environment in which a child with Cerebral Palsy lives or adapting himself according to the environment facilitates independence in daily life activities. There is a need for practical performance tests to evaluate the gait adaptation of children with cerebral palsy in the clinic. However, no study has been found to evaluate gait adaptation in children with cerebral palsy. Therefore, the aim of the study is to evaluate the validity and reliability of the WALK test, which was previously developed for children with special learning disabilities, in individuals with cerebral palsy.

According to the International Classification of Functioning, Disability, and Health, physical, social, and behavioral environmental factors; can affect a child's disability, activity limitations, and participation. Adapting the environment in which a child with Cerebral Palsy lives or adapting himself according to the environment facilitates independence in daily life activities. There is a need for practical performance tests to evaluate the gait adaptation of children with cerebral palsy in the clinic. However, no study has been found to evaluate gait adaptation in children with cerebral palsy. Therefore, the aim of the study is to evaluate the validity and reliability of the WALK test, which was previously developed for children with special learning disabilities, in individuals with cerebral palsy. The study will be conducted by Afyonkarahisar University Faculty of Health Sciences.

Eligibility Criteria:
Inclusion Criteria:

* 6-18 years of age;
* Diagnosed with Diparetic, Hemiparetic or Quadriparetic cerebral palsy;
* GMFCS value being ≤3.
* Communication Function Classification System (CFCS) for individuals with Cerebral Palsy ≤3.
* Children with a Modified Ashworth Scale (MASH) ≤ 3 for lower extremity muscles
* Ability to follow verbal commands
* Ability to recognize colors or numbers
* Able to walk ≥10 meters independently with or without an assistive device (orthotics or walking aid)

Exclusion Criteria:

* Presence of serious hearing, vision or cognitive problems,
* Nerve block injection or orthopedic surgery in the last 6 months (such as Botox injection or muscle lengthening surgery)
* Joint contracture
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. In the first part of the study, participants will get one injection once a week until they reach the planned dose. The second part of the study, which might last a couple of months, is a transition period, where participant will get three injections, taken right after each other, once a week. The duration of the study intervention (trial product and lifestyle intervention) will be 72 weeks followed by a 9-week follow-up period without study interventions.


Eligibility Criteria:
Inclusion Criteria:

* Male or female.
* Age above or equal to 18 years at the time of signing informed consent.
* Body mass index (BMI) greater than or equal to 30.0 kilogram per square meter (kg/m\^2).
* History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria:

* HbA1c greater than or equal to 48 millimoles per mole (mmol/mol) (6.5 percent) as measured by the central laboratory at screening.
* History of type 1 or type 2 diabetes.
* Treatment with glucose-lowering agent(s) within 90 days before screening.
* A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening irrespective of medical records.
* Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
Oral Lichen Planus Treatment

Oral lichen planus (OLP) is a chronic inflammatory and immune-mediated disease affecting the oral mucosa. OLP presents with asymptomatic, lacelike white stripes and/or symptomatic red, ulcerated mucous membranes. Eating, drinking and oral hygiene procedures may be painful resulting in reduced quality of life (QOL). Photodynamic therapy (PDT) is a new suggestion for OLP treatment PDT is a successful treatment mo- dality for premalignant and malignant diseases of head and neck,gastrointestinal tract, lung, and skin

In this study, the effect of photodynamic therapy with topical corticosteroid in oral lichen planus patients was compared

In this study, the efficacy of toluidine blue-mediated photodynamic therapy and topical triamcinolone acetonide 0.2% on decreasing pain and size of OLP lesions was compared.

This randomized, clinical trial compared the therapeutic effect of photodynamic therapy on symptomatic OLP (atrophic/ erosive/ulcerative forms) with triamcinolone acetonide 0.2%. The protocol of the clinical trial, which was conducted according to the ethical principles of Helsinki Group I toluidine blue-mediated photodynamic therapy Group II photodynamic therapy GroupIII laser sham + triamcinolone acetonide 0.2%

Eligibility Criteria:
Inclusion Criteria:

* . The patients with clinical or histopathological diagnosis of bilateral atrophic or erosive OLP (symptomatic OLP) who signed the written consent form were recruited.

Exclusion Criteria:

* Patients with drug-induced or contact lichenoid reactions, patients receiving any treatment for OLP in 2 months prior to the study, pregnant or lactating women, patients with uncontrolled systemic disease, and patients with photosensitivity
Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies

This project will clarify the potential interaction between HBV infection and steatosis, and their impact on genetic alterations and tumor immune microenvironment.

This study will start with a "training cohort" of the NTUH and NTU Cancer Center patients, consisting of 4 sub-groups: HBV (+) steatosis (+), HBV (-) steatosis (+), HBV (+) steatosis (-) and HBV (-) steatosis (-). HBV (+) is defined as either: (a) HBsAg (+) or (b) HBsAg (-) anti-HBc (+) and HBV DNA detectable in blood or tumor tissue. Steatosis is defined by histology. We will enroll 400 patients who had sufficient tissue for testing in the training cohort. The following studies will be performed: (1) NGS of targeted genes panel using the National Health Research Institutes precision medicine platform; (2) transcriptomic analysis of immune microenvironment using RNA-seq and multiplex immunofluorescence staining; (3) lipotoxic genotyping for SNPs; (4) clinical outcomes of MAFLD vs. non-MAFLD. The genetic and immunological features will be further tested by a "validation cohort", from collaborative hospitals. This project will clarify the potential interaction between HBV infection and steatosis, and their impact on genetic alterations and tumor immune microenvironment.

Eligibility Criteria:
Inclusion Criteria:

1. Adult female or male patients aged ≥20 years.
2. HCC has been histologically confirmed with resection specimen.
3. The surgery should be performed with curative intent after 2015 in the study hospital.
4. Availability of serum HBsAg and Anti-HBc data in the electronic medical record.
5. Availability of imaging data performed within 3 months before the surgery in the electronic medical record. (at least one of the following: computed tomography, magnetic resonance imaging, abdominal sonography).
6. Informed consent is obtained. Willingness to provide the residual operative slides and medical records.

Exclusion Criteria:

1. Fibrolamellar HCC, sarcomatoid HCC, or a mixture of cholangiocarcinoma and HCC
2. Exclusion of HCV patients (Anti-HCV positive)
3. Inability to cooperate by providing a complete medical history.